Biospecimen Unit
Biospecimen Unit
批准号:
10016227
负责人:
Kristina Ann Cole
金额:
$19.2万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-30 至 2023-08-31
关键词:
ArchitectureAtlasesAutopsyB-Cell Acute Lymphoblastic LeukemiaB-LymphocytesBlood specimenCellsCessation of lifeChildChildhoodChildhood GliomaChromatinClinicalCommunitiesData AnalysesDatabasesDiagnosisDiagnostic radiologic examinationDiseaseEnsureEvolutionGenomeGenomicsGliomaGoalsHumanHuman ResourcesImmuneImmunotherapyIn SituInfrastructureInstitutionKnowledgeLeadershipMalignant Childhood NeoplasmMalignant NeoplasmsMissionModernizationMolecularNeuroblastomaOncologistOperative Surgical ProceduresPathologicPathologistPatientsPediatric NeoplasmProcessRecurrenceRelapseResearchResistanceResolutionResource SharingRoleSamplingSpace PerceptionSpecimenStreamStructureSurgeonSystemTherapeuticTimeTissuesTumor TissueTumor-Associated Processbiobankchemotherapychimeric antigen receptor T cellsdata sharinghigh riskmethylomemultidisciplinarymultiple omicsneoplastic cellnovel therapeuticsprospectiveresponsestandard of caresuccesstargeted treatmenttherapy developmenttranscriptometumor
中文摘要
摘要
生物标本股的目标是提供必要的基础设施,
前瞻性地获取最高质量的人类肿瘤标本,以支持使命
儿科肿瘤细胞图谱中心(CPTCA)我们现有的生物储存库
基础设施现代化,精简,并得到我们机构的大力支持。我们
在几个类似的大规模多机构项目中,领导作用发生了变化
特定儿科癌症的治疗方法和护理标准,并提供
这进一步证明,确保CPTCA成功的结构已经到位。
我们将前瞻性地收集20名患者的肿瘤和血液样本,
主要的儿科癌症。我们提出以下三个具体目标:1)获得,
处理和表征用于CPTCA的儿科高级别胶质瘤生物标本
检查从诊断到复发的关键基因组转变; 2)为了获得,
处理和表征儿科高危神经母细胞瘤生物标本,
CPTCA用于定义肿瘤演变和对化疗的克隆动态反应,
3)获取、处理和表征儿科极高危B细胞
用于演变的CPTCA的急性淋巴细胞白血病(VHR ALL)生物标本
通过标准疗法和CAR-T细胞免疫疗法治疗疾病。完成时
为此,我们将向鉴定组提供高质量的生物标本,
综合的多组学和原位分析,
临床、分子、病理和放射学数据库。
英文摘要
Abstract
The objective of the Biospecimen Unit is to provide the necessary infrastructure to
prospectively acquire the highest quality human tumor specimens to support the mission
of the Center for Pediatric Tumor Cell Atlas (CPTCA). Our existing biorepository
infrastructure is modern, stream-lined and highly supported by our institution. Our
leadership role in several similar, large scale multi-institutional projects have changed
the therapeutic approach and standard of care of specific pediatric cancers and provide
further evidence that the structure is already in place to ensure the success of CPTCA.
We will prospectively collect tumor and blood samples from twenty patients for three
major pediatric cancers. We propose the following three specific aims: 1) To acquire,
process and characterize pediatric high-grade glioma biospecimens for the CPTCA
examining the critical genomic transitions from diagnosis to relapse; 2) To acquire,
process and characterize pediatric high-risk neuroblastoma biospecimens for the
CPTCA to define tumor evolution and the clonal dynamic response to chemotherapy and
targeted therapy; 3) To acquire, process and characterize pediatric very high-risk B-cell
acute lymphoblastic leukemia (VHR ALL) biospecimens for the CPTCA for the evolution
of disease through standard therapy and CAR-T cell immunotherapy. At the completion
of this aim, we will provide high quality biospecimens to the Characterization Unit for
comprehensive multi-omic and in situ analyses integrated with a highly annotated
clinical, molecular, pathologic and radiographic database.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Biospecimen Unit
-
批准号:10251226
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2018
-
负责人:Kristina Ann Cole
-
依托单位:
Translational Genomics of MicroRNAs in Neuroblastoma
-
批准号:8096805
-
项目类别:
-
资助金额:$16.18万
-
财政年份:2009
-
负责人:Kristina Ann Cole
-
依托单位:
Translational Genomics of MicroRNAs in Neuroblastoma
-
批准号:8507170
-
项目类别:
-
资助金额:$16.18万
-
财政年份:2009
-
负责人:Kristina Ann Cole
-
依托单位:
Translational Genomics of MicroRNAs in Neuroblastoma
-
批准号:8277793
-
项目类别:
-
资助金额:$16.18万
-
财政年份:2009
-
负责人:Kristina Ann Cole
-
依托单位:
Translational Genomics of MicroRNAs in Neuroblastoma
-
批准号:7570880
-
项目类别:
-
资助金额:$15.43万
-
财政年份:2009
-
负责人:Kristina Ann Cole
-
依托单位:
Translational Genomics of MicroRNAs in Neuroblastoma
-
批准号:7882614
-
项目类别:
-
资助金额:$15.8万
-
财政年份:2009
-
负责人:Kristina Ann Cole
-
依托单位:
Biospecimen Unit
-
批准号:9791166
-
项目类别:
-
资助金额:$19.2万
-
财政年份:--
-
负责人:Kristina Ann Cole
-
依托单位:
海外基金